Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …

Objective This study aimed to determine the effects of a long‐acting glucagon‐like peptide‐1
(GLP‐1) receptor agonist, liraglutide, and placebo subcutaneously over 16 weeks on weight …

Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and
body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We …

There has been an alarming increase in the prevalence of obesity in people with type 1
diabetes in recent years. Although obesity has long been recognized as a major risk factor …

The preproglucagon gene (Gcg) is expressed by specific enteroendocrine cells (L-cells) of
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …

Gastric emptying is a major determinant of postprandial blood glucose, accounting for~ 35%
of variance in peak glucose in both healthy individuals and those with type 2 diabetes …

The processing of proglucagon in intestinal L cells results in the formation of glucagon, GLP-
1, and GLP-2. The GLP-1 molecule becomes active through the effect of proconvertase 1 …

The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as
liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide …

Abstract Glucagon-like peptide 1 (GLP-1) is a cleavage product of the pre-proglucagon gene
which is expressed in the α-cells of the pancreas, the L-cells of the intestine, and neurons …